Mizuho Initiates Coverage On Bicara Therapeutics with Neutral Rating, Announces Price Target of $18
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Mizuho analyst Joseph Catanzaro initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Neutral rating and announces Price Target of $18.
Mizuho analyst Joseph Catanzaro initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Neutral rating and announces Price Target of $18.